A. Ruiz

Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy

Ander Urruticoechea, Mohammed Rizwanullah, Seock‐Ah Im et al. · Journal of Clinical Oncology · 2017 · 122 citations

Medicine, Oncology, Pharmacology +17

First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

Enrique Aranda, Pilar García‐Alfonso, Manuel Benavides et al. · European Journal of Cancer · 2018 · 82 citations

Medicine, Oncology, Pharmacotherapy +16

Phase Ii Study of First-Line Mfolfox Plus Cetuximab (C) for 8 Cycles Followed By Mfolfox Plus C or Single Agent (S/A) C As Maintenance Therapy in Patients (P) with Metastatic Colorectal Cancer (Mcrc): the Macro-2 Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [Ttd])

Pilar Alfonso, Manuel Benavides, A. Ruiz et al. · Annals of Oncology · 2014 · 18 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Peritoneal washing is an adequate source for somatic BRCA1/2 mutation testing in ovarian malignancies

Miguel Barquín, Constanza Maximiano, Clara Pérez-Barrios et al. · Pathology - Research and Practice · 2018 · 15 citations

Medicine, Gynecology, Oncology +16

Multicenter, randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer comparing tac with fac: 5-year efficacy analysis of the GEICAM 9805 trial

M. González Martín, A. Iluch, Miguel Ángel Seguí et al. · Journal of Clinical Oncology · 2008 · 14 citations

Medicine, Oncology, Pharmacology +17